dabrafenib
Selected indexed studies
- Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. (N Engl J Med, 2024) [PMID:38899716]
- Dabrafenib. (Recent Results Cancer Res, 2014) [PMID:24756796]
- Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. (N Engl J Med, 2023) [PMID:37733309]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. (2024) pubmed
- Dabrafenib. (2014) pubmed
- Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. (2023) pubmed
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. (2017) pubmed
- Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. (2017) pubmed
- Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis. (2023) pubmed
- Improved overall survival in melanoma with combined dabrafenib and trametinib. (2015) pubmed
- Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma. (2023) pubmed
- Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. (2022) pubmed
- Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. (2022) pubmed